| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
1 The Broad Institute of the Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts; 2 The Simons Center for Systems Biology, Institute for Advanced Study, Princeton, New Jersey; 3 Molecular Biology, Cellular Biology and Biochemistry Program, 4 Department of Biomedical Engineering, Boston University, Boston, Massachusetts; 5 Yale Cancer Center and 6 Department of Pathology, Yale University School of Medicine, New Haven, Connecticut; 7 Robert Wood Johnson University Hospital, and 8 Cancer Institute of New Jersey, New Brunswick, New Jersey; and 9 BioMaPS Institute and Department of Biomedical Engineering, Rutgers University, Piscataway, New Jersey
Requests for reprints: Gyan Bhanot, BioMaPs Institute, Rutgers University, 271 Hill Center, Piscataway, NJ 08854. Phone: 732-235-9545; E-mail: gyanbhanot{at}gmail.com and Shridar Ganesan, Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903. Phone: 732-235-5211; E-mail: ganesash{at}umdnj.edu.
Gene expression analysis has identified biologically relevant subclasses of breast cancer. However, most classification schemes do not robustly cluster all HER2+ breast cancers, in part due to limitations and bias of clustering techniques used. In this article, we propose an alternative approach that first separates the HER2+ tumors using a gene amplification signal for Her2/neu amplicon genes and then applies consensus ensemble clustering separately to the HER2+ and HER2– clusters to look for further substructure. We applied this procedure to a microarray data set of 286 early-stage breast cancers treated only with surgery and radiation and identified two basal and four luminal subtypes in the HER2– tumors, as well as two novel and robust HER2+ subtypes. HER2+ subtypes had median distant metastasis-free survival of 99 months [95% confidence interval (95% CI), 83–118 months] and 33 months (95% CI, 11–54 months), respectively, and recurrence rates of 11% and 58%, respectively. The low recurrence subtype had a strong relative overexpression of lymphocyte-associated genes and was also associated with a prominent lymphocytic infiltration on histologic analysis. These data suggest that early-stage HER2+ cancers associated with lymphocytic infiltration are a biologically distinct subtype with an improved natural history. [Cancer Res 2007;67(22):10669–76]
This article has been cited by other articles:
![]() |
F. Correa Geyer and J. S. Reis-Filho Microarray-based Gene Expression Profiling as a Clinical Tool for Breast Cancer Management: Are We There Yet? International Journal of Surgical Pathology, August 1, 2009; 17(4): 285 - 302. [Abstract] [PDF] |
||||
![]() |
G. Alexe, J. Monaco, S. Doyle, A. Basavanhally, A. Reddy, M. Seiler, S. Ganesan, G. Bhanot, and A. Madabhushi Towards Improved Cancer Diagnosis and Prognosis Using Analysis of Gene Expression Data and Computer Aided Imaging Experimental Biology and Medicine, August 1, 2009; 234(8): 860 - 879. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schmidt, J. G. Hengstler, C. von Torne, H. Koelbl, and M. C. Gehrmann Coordinates in the Universe of Node-Negative Breast Cancer Revisited Cancer Res., April 1, 2009; 69(7): 2695 - 2698. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schmidt, D. Bohm, C. von Torne, E. Steiner, A. Puhl, H. Pilch, H.-A. Lehr, J. G. Hengstler, H. Kolbl, and M. Gehrmann The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer Cancer Res., July 1, 2008; 68(13): 5405 - 5413. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |